1-8 of 8
Kelly S. Oliner
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Timothy J. Price, Andrés Cervantes, Alberto F. Sobrero, Michel Ducreux, Yevhen Hotko, Thierry André, Emily Chan, Florian Lordick, Cornelis J.A. Punt, Andrew H. Strickland, Gregory Wilson, Tudor E. Ciuleanu, Laslo Roman, Eric Van Cutsem, Pei He, Hua Yu, Reija Koukakis, Jan-Henrik Terwey, Andre S. Jung, Roger Sidhu, Scott D. Patterson
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (24): 5469–5479.
https://doi.org/10.1158/1078-0432.CCR-15-0526
Published: 14 December 2015
View article titled, Analysis of <em>KRAS</em>/<em>NRAS</em> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer
Open the PDF for Analysis of <em>KRAS</em>/<em>NRAS</em> Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer

Sameer Doshi, Per Olsson Gisleskog, Yilong Zhang, Min Zhu, Kelly S. Oliner, Elwyn Loh, Juan Jose Perez Ruixo
Journal: Clinical Cancer Research
Clin Cancer Res (2015) 21 (11): 2453–2461.
https://doi.org/10.1158/1078-0432.CCR-14-1661
Published: 31 May 2015
View article titled, Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer
Open the PDF for Rilotumumab Exposure–Response Relationship in Patients with Advanced or Metastatic Gastric Cancer in another window
Includes: Supplementary data
Journal Articles

Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type KRAS Metastatic Colorectal Cancer

Eric Van Cutsem, Cathy Eng, Elzbieta Nowara, Anna Świeboda-Sadlej, Niall C. Tebbutt, Edith Mitchell, Irina Davidenko, Joe Stephenson, Elena Elez, Hans Prenen, Hongjie Deng, Rui Tang, Ian McCaffery, Kelly S. Oliner, Lisa Chen, Jennifer Gansert, Elwyn Loh, Dominic Smethurst, Josep Tabernero
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (16): 4240–4250.
https://doi.org/10.1158/1078-0432.CCR-13-2752
Published: 13 August 2014
View article titled, Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <em>KRAS</em> Metastatic Colorectal Cancer
Open the PDF for Randomized Phase Ib/II Trial of Rilotumumab or Ganitumab with Panitumumab versus Panitumumab Alone in Patients with Wild-type <em>KRAS</em> Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer

Marc Peeters, Kelly S. Oliner, Alex Parker, Salvatore Siena, Eric Van Cutsem, Jing Huang, Yves Humblet, Jean-Luc Van Laethem, Thierry André, Jeffrey Wiezorek, David Reese, Scott D. Patterson
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (7): 1902–1912.
https://doi.org/10.1158/1078-0432.CCR-12-1913
Published: 02 April 2013
View article titled, Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer
Open the PDF for Massively Parallel Tumor Multigene Sequencing to Evaluate Response to Panitumumab in a Randomized Phase III Study of Metastatic Colorectal Cancer in another window
Includes: Supplementary data
Journal Articles

Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone

Charles J. Ryan, Mark Rosenthal, Siobhan Ng, Joshi Alumkal, Joel Picus, Gwenaëlle Gravis, Karim Fizazi, Frédéric Forget, Jean-Pascal Machiels, Sandy Srinivas, Min Zhu, Rui Tang, Kelly S. Oliner, Yizhou Jiang, Elwyn Loh, Sarita Dubey, Winald R. Gerritsen
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (1): 215–224.
https://doi.org/10.1158/1078-0432.CCR-12-2605
Published: 02 January 2013
View article titled, Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone
Open the PDF for Targeted MET Inhibition in Castration-Resistant Prostate Cancer: A Randomized Phase II Study and Biomarker Analysis with Rilotumumab plus Mitoxantrone and Prednisone in another window
Includes: Supplementary data
Journal Articles

Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer

Quynh-Thu Le, Richard Fisher, Kelly S. Oliner, Richard J. Young, Hongbin Cao, Christina Kong, Edward Graves, Rodney J. Hicks, Grant A. McArthur, Lester Peters, Brian O'Sullivan, Amato Giaccia, Danny Rischin
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (6): 1798–1807.
https://doi.org/10.1158/1078-0432.CCR-11-2094
Published: 14 March 2012
View article titled, Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer
Open the PDF for Prognostic and Predictive Significance of Plasma HGF and IL-8 in a Phase III Trial of Chemoradiation with or without Tirapazamine in Locoregionally Advanced Head and Neck Cancer in another window
Includes: Supplementary data
Journal Articles

A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors

Peter J. Rosen, Christopher J. Sweeney, Dorothy J. Park, Darrin M. Beaupre, Hongjie Deng, Ian M. Leitch, Poornima Shubhakar, Min Zhu, Kelly S. Oliner, Abraham Anderson, Lorrin K. Yee
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (9): 2677–2687.
https://doi.org/10.1158/1078-0432.CCR-09-2862
Published: 28 April 2010
View article titled, A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors
Open the PDF for A Phase Ib Study of AMG 102 in Combination with Bevacizumab or Motesanib in Patients with Advanced Solid Tumors in another window
Journal Articles

Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors

Michael S. Gordon, Christopher J. Sweeney, David S. Mendelson, S. Gail Eckhardt, Abraham Anderson, Darrin M. Beaupre, Daniel Branstetter, Teresa L. Burgess, Angela Coxon, Hongjie Deng, Paula Kaplan-Lefko, Ian M. Leitch, Kelly S. Oliner, Lucy Yan, Min Zhu, Lia Gore
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (2): 699–710.
https://doi.org/10.1158/1078-0432.CCR-09-1365
Published: 14 January 2010
View article titled, Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors
Open the PDF for Safety, Pharmacokinetics, and Pharmacodynamics of AMG 102, a Fully Human Hepatocyte Growth Factor–Neutralizing Monoclonal Antibody, in a First-in-Human Study of Patients with Advanced Solid Tumors in another window
Includes: Supplementary data